The FY2026 results are a non-event for a pre-revenue biotech — the stock will trade on pipeline catalysts, not financials. Key catalysts to watch: IBIO-600 multiple ascending dose data (timeline undisclosed), IBIO-610 IND filing, and any partnership/licensing deal for the amylin program. The ATM facility introduces potential dilution overhang but is standard for clinical-stage companies.
Price Chart
Executive Summary
iBio reported fiscal year 2026 (FYE June 30) results: revenue of $0.1M (down from $0.4M YoY) and a net loss of $33.0M (vs $18.4M loss in FY2025), driven by a $11.3M increase in R&D spend and a $5.0M impairment charge. The company ended the year with $88.0M in cash and equivalents, extending its cash runway into FY2028. While pipeline progress (Phase 1 data for IBIO-600, IND-enabling for IBIO-610/800) is notable, the widening operating loss and lack of near-term revenue catalysts cap the upside for a pre-commercial biotech at a $70M market cap.
Key Financial Metrics
Key Facts
- Revenue for FY2026 was $0.1M, down from $0.4M in FY2025.
- Net loss widened to $33.0M from $18.4M YoY, driven by higher R&D ($19.6M vs $8.3M) and a $5.0M impairment of IBIO-101 intangible asset.
- Cash and investments totaled $88.0M as of June 30, 2026, with cash runway extended into FY2028.
- IBIO-600 Phase 1 single ascending dose portion completed (31 of 32 participants dosed); multiple ascending dose portion being prepared.
- IBIO-610 advanced into IND-enabling studies; preclinical data showed fat-selective weight loss and combination benefit with semaglutide.
- IBIO-800 (myostatin/Activin A bispecific) entered IND-enabling development; initial focus on PH-HFpEF.
- In-licensed AstralBio's amylin receptor antibody program (AMY1, AMY3, dual amylin/calcitonin agonists).
- Closed a $26M private placement in January 2026 and entered an ATM facility for up to $100M in common stock sales.
- Loss per share was $(0.32) on 104.1M weighted-average shares, vs $(1.75) on 10.5M shares in FY2025.
Financial Impact
Net loss of $33.0M on $0.1M revenue; cash burn rate ~$35M/year; $88M cash runway into FY2028
Risk Factors
- No approved products or near-term revenue; continued operating losses require future financing.
- Dilution risk from the $100M ATM facility and potential future equity offerings.
- Clinical development risk: IBIO-600/610/800 are early-stage with no proof-of-concept in humans yet.
- Impairment of IBIO-101 intangible asset ($5.0M) suggests prior pipeline value write-downs may recur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001420720-26-000019 |
| Document: 0001420720-26-000019-index.html | 0001420720-26-000019 |
| Document: 0001420720-26-000019.txt | 0001420720-26-000019 |
| 8-K Data (Synthetic) | 0001420720-26-000019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7100 (−13.52%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7100 (−9.07%) |
Oct 13, 2026 13d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7100 (−9.18%) |
Sep 14, 2026 6w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7100 (−40.34%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7100 (−47.79%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7100 (−47.79%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7100 (−59.43%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7100 (−51.70%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7100 (+54.19%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7100 (−57.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers